Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, Keun Seok Lee et al.|New England Journal of Medicine|2022Cited by 2.5k
Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cellsJunji Tsurutani, Phillip A. Dennis|Carcinogenesis|2005Cited by 289
DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistanceNaoki Takegawa, Junji Tsurutani|International Journal of Cancer|2017Cited by 193
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 StudyAditya Bardia, Funda Meric‐Bernstam, Ian E. Krop et al.|Journal of Clinical Oncology|2024Cited by 158
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1Yoshikane Nonagase, Junji Tsurutani|Oncotarget|2016Cited by 25